Establishment of a therapeutic model for retroviral infection using the genetic resistance mechanism of the host

Pathology International

Volumn 46, Issue 10, 1996, Pages 719-725

  Kitagawa, Masanobu ^a   Aizawa, Shiro ^b   Ikeda, Hidetoshi ^c   Hirokawa, Katsuiku ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

Author keywords

bone marrow transplantation; Fv 4; gene therapy; receptor interference; retrovirus

Indexed keywords

GENE PRODUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW TRANSPLANTATION; CHROMOSOME 12; GENE THERAPY; HOST RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; VIRUS CELL INTERACTION; VIRUS RESISTANCE;

EID: 0029806783     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1996.tb03540.x     Document Type: Review

References (73)

1. Gardner MB, Luciw PA. Animal models of AIDS. FASEB J. 1989; 3: 2593-2606.
2. Gardner MB. Simian and feline immunodeficiency viruses: Animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. Antiviral Res. 1991; 15: 267-286.
3. Kitagawa M, Lackner AA, Martfeld DJ, Gardner MB, Dandekar S. Simian immunodeficiency virus infection of macaque bone marrow macrophages correlates with disease progression in vivo. Am. J. Pathol. 1991; 138: 921-930.
4. Lilly F, Pincus T. Genetic control of murine viral leukemogenesis. Adv. Cancer Res. 1973; 17: 231-277.
5. Chesebro B, Miyazawa M, Britt WJ. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Ann. Rev. Immunol. 1990; 8: 477-499.
6. Kitagawa M, Matsubara O, Kasuga T. Relation between Friend leukemia virus-induced leukemia and genetic control of the host. Bull. Tokyo Med. Dent. Univ. 1983; 30: 95-107.
7. 1 mice and differentiation of FLV-induced leukemia. Histol. Histopathol. 1986; 1: 335-340.
8. Miyazawa M, Nishio J, Wehrly K, David CS, Chesebro B. Spontaneous recovery from Friend retrovirus-induced leukemia: Mapping of the Rfv-2 gene in the Q/TL region of mouse MHC. J. Immunol. 1992; 148: 1964-1967.
9. Perry LL, Miyazawa M, Hasenkrug K, Wehrly K, David CS, Chesebro B. Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia. J. Virol. 1994; 68: 4921-4926.
10. Miyazawa M, Nishio J, Wehrly K, Chesebro B. Influence of MHC genes on spontaneous recovery from Friend retrovirus-induced leukemia. J. Immunol. 1992; 148: 644-647.
11. Malo D, Skamene E. Genetic control of host resistance to infection. Tr. Genetics 1994; 10: 365-371.
12. Li JP, D'Andrea AD, Lodish HG, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 1990; 343: 762-764.
13. r resistance gene. Proc. Natl Acad. Sci. USA 1990; 87: 9985-9989.
14. Del Rizzo DF, Eskinazi D, Axelrad AA. Negative regulation of DNA synthesis in early erythropoietic progenitor cells (BFU-E) by a protein purified from the medium of C57BL/6 mouse marrow cells. Proc. Natl Acad. Sci. USA 1988; 85: 4320-4324.
15. Ben-David Y, Bernstein A. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 1981; 66: 831-834.
16. Evans LH, Morrison RP, Malik FG, Portis J, Britt WJ. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J. Virol. 1990; 64: 6176-6183.
17. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 1985; 135: 2183-2186.
18. Green WR, Green KA, Crassi KM. Adoptive transfer of polyclonal and cloned cytolytic T lymphocytes (CTL) specific for mouse AIDS-associated tumors is effective in preserving CTL responses: A measure of protection against LP-BM5 retrovirus-induced immunodeficiency. J. Virol. 1994; 68: 4679-4684.
19. Hein A, Czub S, Xiao LX, Schwender S, Dorries R, Czub M. Effects of adoptive immune transfers on murine leukemia virus-infection of rats. Virology 1995; 211: 408-417.
20. Miyazawa M, Fujisawa R, Ishihara C et al. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J. Immunol. 1995; 155: 748-758.
21. Klinman DM, Krieg A, Conover J, Ussery MA, Black PL. Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS. AIDS Res. Hum. Retroviruses 1992; 8: 101-106.
22. Shen R-N, Hornback NB, Lu L, Young P, Brahmi Z, Broxmeyer HE. Curative effect of split low dosage total-body irradiation on mice infected with the polycythemia-inducing strain of the Friend virus complex. Cancer Res. 1988; 48: 2399-2403.
23. Ruprecht RM, Koch JA, Sharma PL, Armany RS. Development of antiviral treatment strategies in murine models. AIDS Res. Hum. Retroviruses 1992; 8: 997-1011.
24. Kitagawa M, Kamisaku H, Sado T, Kasuga T. Friend leukemia virus-induced leukemogenesis in fully H-2-incompatible C57BL/ 6→C3H radiation bone marrow chimeras. Leukemia 1993; 7: 1041-1046.
25. Kitagawa M, Kamisaku H, Aizawa S, Sado T. Bone marrow transplantation from Fv-4-resistant donors rescues Friend leukemia virus-infected mice from leukemia: A model of bone marrow transplantation therapy against retroviral infection. Leukemia 1994; 8: 2200-2206.
26. Iwai H, Day NK, Hamada N, Inaba MM, Ikehara S, Good RA. Bone marrow transplantation therapy using resistant donors for retrovirus-induced leukemia in mice. Clin. Exp. Immunol. 1994; 95: 135-140.
27. European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukemia in Europe (Report from the Working Party on Leukemia). Lancet 1988; 1: 1379-1382.
28. Wijnaendts L, Le Deist F, Griscelli C, Fischer A. Development of immunologic functions after bone marrow transplantation in 33 patients with severe combined immunodeficiency. Blood 1989; 245: 1132-1139.
29. Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1993; 79: 269-275.
30. Contu L, La Nasa G, Arras M et al. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS. Bone Marrow Transplant. 1993; 12: 669-671.
31. Turner ML, Watson HG, Russel L, Langlands K, Ludlam CA, Parker AC. An HIV positive haemophiliac with acute lymphoblastic leukaemia successfully treated with intensive chemotherapy and syngeneic bone marrow transplantation. Bone Marrow Transplant. 1992; 9: 387-389.
32. Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: Report from the international bone marrow transplant registry. Natl Immun. Cell Growth Regul. 1988; 7: 334-350.
33. Sado T, Kamisaku H. Histocompatibility and T-B cell cooperation in mouse radiation chimeras. J. Immunol. 1975; 115: 1607-1612.
34. Kitagawa M, Matsubara O, Kasuga T. Dynamics of lymphocytic subpopulations in Friend leukemia virus-induced leukemia. Cancer Res. 1986; 46: 3034-3039.
35. Van der Gaag HC, Axelrad AA, Friend virus replication in normal and immunosuppressed C57BL/6 mice. Virology 1990; 177: 837-839.
36. Suzuki S. Fv-4: A new gene affecting the splenomegaly induction by Friend leukemia virus. Jpn. J. Exp. Med. 1975; 45: 473-478.
37. Kai K, Ikeda H, Yuasa Y, Suzuki S, Odaka T. Mouse strain resistant to N-, B-, and NB-tropic murine leukemia viruses. J. Virol. 1976; 20: 436-440.
38. Ikeda H, Odaka T. Cellular expression of murine leukemia virus gp70-related antigen on thymocytes of uninfected mice correlated with Fv-4 gene-controlled resistance to Friend leukemia virus infection. Virology 1983; 128: 127-139.
39. Ikeda H, Odaka T. A cell membrane 'gp70' associated with Fv-4 gene: Immunological characterization, and tissue and strain distribution. Virology 1984; 133: 65-76.
40. Ikeda H, Sugimura H. Fv-4 resistance gene: A truncated endogenous murine leukemia virus with ecotropic interference properties. J. Virol. 1989; 63: 5405-5412.
41. Limjoco TI, Dickie P, Ikeda H, Silver J. Transgenic Fv-4 mice resistant to Friend virus. J. Virol. 1993; 67: 4163-4168.
42. Corbin A, Richardson J, Denesvre C, Pozo F, Ellerbrok H, Sitbon M. The envelopes of two ecotropic murine leukemia viruses display distinct efficiencies in retroviral vaccination by interference. Virology 1994; 202: 70-75.
43. Corbin A, Sitbon M. Protection against retroviral diseases after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses. J. Virol. 1993; 67: 5146-5152.
44. Kitagawa M, Aizawa S, Kamisaku H, Ikeda H, Hirokawa K, Sado T. Cell-free transmission of Fv-4 resistance gene product controlling Friend leukemia virus-induced leukemogenesis: A unique mechanism for interference with viral infection. Blood 1995; 86: 1557-1563.
45. Nihrane A, Fujita K, Willey R et al. Murine leukemia virus envelope protein in transgenic mouse serum blocks infection in vitro. J. Virol. 1996; 70: 1882-1889.
46. Kim JW, Closs EI, Albritton LM, Cunningham JM. Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 1991; 352: 725-728.
47. r mouse strain. Exp. Hematol. 1996 (in press).
48. Matano T, Odawara T, Ohshima M, Yoshikura H, Iwamoto A. Trans-dominant interference with virus infection at two different stages by a mutant envelope protein of Friend murine leukemia virus. J. Virol. 1993; 67: 2026-2033.
49. Matano T, Odawara T, Ohshima M, Iwamoto A, Yoshikura H. Interaction between the dominant negative mutant and wildtype envelope proteins of Friend murine leukemia virus. J. Virol. 1994; 68: 6079-6082.
50. Battini J-L, Danos O, Heard JM. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J. Virol. 1995; 69: 713-719.
51. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987; 238: 1704-1707.
52. Hussey RE, Richardson NE, Kowalski M et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78-81.
53. Morgan RA, Baler-Bitterlich G, Ragheb JA, Wong-Staal F, Gallo RC, Anderson WF. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: Demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. AIDS Res. Hum. Retroviruses 1994; 10: 1507-1515.
54. Lifson JD, Hwang KM, Nara PL et al. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 1988; 241: 712-716.
55. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333-348.
56. Byrn RA, Mordenti J, Lucas C et al. Biological properties of a CD4 immunoadhesin. Nature 1990; 344: 667-670.
57. Maddon PJ, McDougal JS, Clapham PR et al. HIV infection does not require endocytosis of its receptor, CD4. Cell 1988; 54: 865-874.
58. Rovinski B, Haynes JR, Cao SX et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: Implication for development of a cross-protective AIDS vaccine. J. Virol. 1992; 66: 4003-4012.
59. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science 1995; 270: 404-410.
60. Blease RM, Culver KW. Gene therapy for primary immunodeficiency disease. Immunodefic. Rev. 1992; 3: 329-349.
61. Yu M, Peschla E, Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Therapy 1994; 1: 113-126.
62. Dropulic B, Jeang KT. Gene therapy for human immunodeficiency virus infection: Genetic antiviral strategies and targets for intervention. Hum. Gene Therapy 1994; 5: 927-939.
63. Bridges SH, Sarver N. Gene therapy and immune restoration for HIV disease. Lancet 1995; 345: 427-432.
64. Gilboa E, Smith C. Gene therapy for infectious diseases: The AIDS model. Tr. Genet. 1994; 10: 139-144.
65. Vieillard V, Lauret E, Rousseau V, De Maeyer E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express Interferon β. Proc. Natl Acad. Sci. USA 1994; 91: 2689-2693.
66. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 1995; 69: 4045-4052.
67. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC. Antitat gene therapy: A candidate for late-stage AlDS patients. Gene Therapy 1995; 2: 218-222.
68. Lee SW, Gallardo HF, Giboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol. 1994; 68: 8254-8264.
69. Schwartz DH. Potential pitfalls on the road to an effective HIV vaccine. Immunol. Today 1994; 15: 54-57.
70. + cell function down-regulation in AIDS patients. J. Immunol. 1992; 148: 2709-2716.
71. Toggas SM, Masliah E, Rockenstein EM, Rail GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367: 188-193.
72. Miller N, Vile R. Targeted vectors for gene therapy. FASEB J. 1995; 9: 190-199.
73. Crise B, Buonocore L, Rose JK. CD4 is retained in the endoplasmic reticulum by the human immunodeficiency virus type 1 glycoprotein precursor. J. Virol. 1990; 64: 5585-5593.